Cabaletta Bio Files for $100 Million IPO

Cabaletta Bio filed the paperwork for their $100 Million IPO on 9/30/19. The Philadelphia, PA based company is developing treatments for a number of autoimmune diseases utilizing the founders' variation of CARs called CAARs or chimeric autoantibody receptors. CAARs are designed to selectively bind with and eliminate pathogenic B cells while sparing normal B cells.  Cabaletta will trade on NASDAQ under the symbol “CABA.”